Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: SYMLIN

« Back to Dashboard

Symlin is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.

The generic ingredient in SYMLIN is pramlintide acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pramlintide acetate profile page.

Summary for Tradename: SYMLIN

Patents:4
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: SYMLIN

Drug ClassAmylin Analog
Mechanism of ActionAmylin Agonists

Clinical Trials for: SYMLIN

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
Status: Completed Condition: Type 1 Diabetes Mellitus

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
Status: Completed Condition: Overweight; Obesity

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
Status: Active, not recruiting Condition: Type 1 Diabetes

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes
Status: Recruiting Condition: Type 2 Diabetes

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
Status: Completed Condition: IDDM

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes
Status: Withdrawn Condition: Type 1 Diabetes

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Status: Completed Condition: Obesity

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
Status: Completed Condition: Overweight; Obesity

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus
Status: Active, not recruiting Condition: Type 2 Diabetes Mellitus

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin
Status: Completed Condition: Obesity

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXYes5,686,411<disabled>YY<disabled>
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Mar 16, 2005DISCNNo6,608,029<disabled><disabled>
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXYes6,114,304<disabled><disabled>
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXNo6,114,304<disabled><disabled>
Astrazeneca Ab
SYMLIN
pramlintide acetate
INJECTABLE;SUBCUTANEOUS021332Sep 25, 2007RXNo5,686,411<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc